Want to see SCYX full AI Analyst Report?
SCYX Stock Chart & Stats
$5.67
-$0.16(-4.29%)
At close: 4:00 PM EDT
$5.67
-$0.16(-4.29%)
Day’s Range― - ―
52-Week Range$3.53 - $9.12
Previous Close$3.57
Volume103.76K
Average Volume (3M)394.91K
Market Cap
$37.66M
Enterprise Value-$4.09M
Total Cash (Recent Filing)$54.08M
Total Debt (Recent Filing)$1.95M
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Nov 11, 2026EPS Estimate
-0.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.84
Shares Outstanding9,949,609
10 Day Avg. Volume79,813
30 Day Avg. Volume394,910
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)0.64
Price to Sales (P/S)1.53
P/FCF Ratio-5.98
Enterprise Value/Market Cap-0.11
Enterprise Value/Revenue-0.21
Enterprise Value/Gross Profit-0.21
Enterprise Value/Ebitda0.40
Forecast
1Y Price Target
$32.00Price Target Upside464.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-2.91
Revenue Forecast (FY)$619.50K
Bulls Say, Bears Say
Bulls Say
Non-dilutive Development FundingThe BARDA cost-share contract can fund substantial eligible development and administrative costs without immediate equity dilution. Its support for SCY-247 and SCY-770 through Phase 2 may extend financial flexibility, preserve the stated cash runway, and advance the antifungal pipeline.
Conservative LeverageVery low leverage gives SCYNEXIS greater flexibility to fund development and absorb operating volatility without the burden of significant debt service. Compared with earlier periods of extreme leverage and thin equity, the current balance sheet provides a stronger foundation for pipeline investment.
Focused Antifungal PlatformA focused antifungal platform with both oral and intravenous delivery addresses serious infections while supporting use across different treatment settings. The core asset and broader pipeline give SCYNEXIS a defined therapeutic identity and a basis for future product and licensing opportunities.
Bears Say
Persistent UnprofitabilityDeeply negative net, EBIT, and EBITDA margins show that current operations are not yet economically self-sustaining. Unless commercialization or licensing economics improve materially, ongoing losses can consume equity, constrain reinvestment, and make durable earnings generation difficult.
Negative Cash GenerationNegative operating and free cash flow means SCYNEXIS is still consuming cash rather than funding operations internally. Although free cash flow improved from 2024, the continuing deficit increases dependence on funding, milestones, or successful commercialization to support development over time.
Revenue And Earnings VolatilityThe sharp revenue contraction and reversal from 2023 profitability to subsequent losses indicate that recent earnings power has not been durable. This volatility makes planning and resource allocation harder, while weakening confidence that current assets can consistently translate into revenue and profit.
SCYNEXIS News
SCYX FAQ
What was SCYNEXIS’s price range in the past 12 months?
SCYNEXIS lowest stock price was $3.53 and its highest was $9.12 in the past 12 months.
What is SCYNEXIS’s market cap?
SCYNEXIS’s market cap is $37.66M.
When is SCYNEXIS’s upcoming earnings report date?
SCYNEXIS’s upcoming earnings report date is Nov 11, 2026 which is in 17 days.
How were SCYNEXIS’s earnings last quarter?
SCYNEXIS released its earnings results on Aug 10, 2026. The company reported $0.63 earnings per share for the quarter, beating the consensus estimate of -$0.507 by $1.137.
Is SCYNEXIS overvalued?
According to Wall Street analysts SCYNEXIS’s price is currently Undervalued.
Does SCYNEXIS pay dividends?
SCYNEXIS does not currently pay dividends.
What is SCYNEXIS’s EPS estimate?
SCYNEXIS’s EPS estimate is -0.72.
How many shares outstanding does SCYNEXIS have?
SCYNEXIS has 9,949,609 shares outstanding.
What happened to SCYNEXIS’s price movement after its last earnings report?
SCYNEXIS reported an EPS of $0.63 in its last earnings report, beating expectations of -$0.507. Following the earnings report the stock price went down -6.208%.
Which hedge fund is a major shareholder of SCYNEXIS?
Currently, no hedge funds are holding shares in SCYX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
SCYNEXIS Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$32.00 (464.37% Upside)
$32.00 (464.37% Upside)
Blogger Sentiment
Bullish
SCYX Sentiment 100%
Sector Average 66%
Sector Average 66%
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 10.7%
Last 30 Days ▲ 10.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-38.55%
12-Months-Change
Fundamentals
Return on Equity
-21.10%
Trailing 12-Months
Asset Growth
23.52%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
SCYNEXIS
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
SCYX Stock 12 Month Forecast
Average Price Target
$32.00
▲(464.37% Upside)
Technical Analysis
Rockwell Med
―
TherapeuticsMD
―
Aytu BioScience
―
Cumberland Pharmaceuticals
―
IM Cannabis Corp
―
Ownership Overview
24.08% Insiders
19.44% Mutual Funds
0.13% Other Institutional Investors
51.88% Public Companies and
Individual Investors